Comments
Loading...

AtriCure Analyst Ratings

ATRCNASDAQ
Logo brought to you by Benzinga Data
$29.29
At close: May 1 EDT
$29.29
0.000.00%
Pre-Market: 4:00 PM EDT
Q1 2025 Earnings were released on Tue Apr 29th, after the market close
The most recent conference call was at 16:30 PM, 3 days ago Click to view past webcast
Consensus Rating1
Buy
Highest Price Target1
$75.00
Lowest Price Target1
$40.00
Consensus Price Target1
$52.58

AtriCure Analyst Ratings and Price Targets | NASDAQ:ATRC | Benzinga

AtriCure Inc has a consensus price target of $52.58 based on the ratings of 12 analysts. The high is $75 issued by SVB Leerink on May 4, 2022. The low is $40 issued by JP Morgan on October 30, 2024. The 3 most-recent analyst ratings were released by UBS, JMP Securities, and Needham on April 30, 2025, respectively. With an average price target of $54 between UBS, JMP Securities, and Needham, there's an implied 84.36% upside for AtriCure Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Dec 24
2
Jan
6
Feb
4
Mar
2
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.4
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

UBS
JMP Securities
Needham
Citizens Capital Markets
Canaccord Genuity

1calculated from analyst ratings

Analyst Ratings for AtriCure

Buy NowGet Alert
04/30/2025Buy Now98.02%UBS
Danielle Antalffy61%
$60 → $58MaintainsBuyGet Alert
04/30/2025Buy Now104.85%JMP Securities
Daniel Stauder48%
$60 → $60ReiteratesMarket Outperform → Market OutperformGet Alert
04/30/2025Buy Now50.22%Needham
Mike Matson56%
$51 → $44MaintainsBuyGet Alert
04/02/2025Buy Now104.85%Citizens Capital Markets
Daniel Stauder48%
$60 → $60ReiteratesMarket Outperform → Market OutperformGet Alert
03/28/2025Buy Now77.53%Canaccord Genuity
William Plovanic58%
$66 → $52MaintainsBuyGet Alert
03/27/2025Buy Now57.05%JP Morgan
Lilia-Celine Lozada30%
$51 → $46MaintainsOverweightGet Alert
03/27/2025Buy Now74.12%Needham
Mike Matson56%
$51 → $51ReiteratesBuy → BuyGet Alert
03/21/2025Buy Now74.12%Needham
Mike Matson56%
$51 → $51ReiteratesBuy → BuyGet Alert
02/13/2025Buy Now53.64%Oppenheimer
Suraj Kalia56%
$36 → $45MaintainsOutperformGet Alert
02/13/2025Buy Now70.71%Piper Sandler
Matt O'Brien51%
$40 → $50MaintainsOverweightGet Alert
02/13/2025Buy Now104.85%JMP Securities
Daniel Stauder48%
$60 → $60ReiteratesMarket Outperform → Market OutperformGet Alert
02/13/2025Buy Now63.88%Stifel
Rick Wise73%
$36 → $48MaintainsBuyGet Alert
02/13/2025Buy Now74.12%Needham
Mike Matson56%
$51 → $51ReiteratesBuy → BuyGet Alert
02/13/2025Buy Now125.33%Canaccord Genuity
William Plovanic58%
$61 → $66MaintainsBuyGet Alert
02/11/2025Buy Now74.12%JP Morgan
Lilia-Celine Lozada30%
$40 → $51MaintainsOverweightGet Alert
02/10/2025Buy Now104.85%JMP Securities
Daniel Stauder48%
$60 → $60ReiteratesMarket Outperform → Market OutperformGet Alert
01/22/2025Buy Now74.12%Needham
Mike Matson56%
$40 → $51MaintainsBuyGet Alert
01/13/2025Buy Now36.57%Needham
Mike Matson56%
$40 → $40ReiteratesBuy → BuyGet Alert
12/17/2024Buy Now36.57%JP Morgan
Lilia-Celine Lozada30%
→ $40Assumes → OverweightGet Alert
12/09/2024Buy Now108.26%Canaccord Genuity
William Plovanic58%
$53 → $61MaintainsBuyGet Alert
10/30/2024Buy Now80.95%Canaccord Genuity
William Plovanic58%
$49 → $53MaintainsBuyGet Alert
10/30/2024Buy Now22.91%Oppenheimer
Suraj Kalia56%
$32 → $36MaintainsOutperformGet Alert
10/30/2024Buy Now36.57%JP Morgan
Robbie Marcus67%
$30 → $40MaintainsOverweightGet Alert
10/30/2024Buy Now36.57%UBS
Danielle Antalffy61%
$35 → $40MaintainsBuyGet Alert
10/30/2024Buy Now36.57%Needham
Mike Matson56%
$34 → $40MaintainsBuyGet Alert
07/31/2024Buy Now80.95%BTIG
Marie Thibault62%
$58 → $53MaintainsBuyGet Alert
07/31/2024Buy Now2.42%JP Morgan
Robbie Marcus67%
$34 → $30MaintainsOverweightGet Alert
07/31/2024Buy Now-11.23%Stifel
Rick Wise73%
$30 → $26MaintainsBuyGet Alert
07/31/2024Buy Now36.57%Piper Sandler
Matt O'Brien51%
$65 → $40MaintainsOverweightGet Alert
07/31/2024Buy Now16.08%Needham
Mike Matson56%
$40 → $34MaintainsBuyGet Alert
07/08/2024Buy Now36.57%Needham
Mike Matson56%
$40 → $40ReiteratesBuy → BuyGet Alert
05/02/2024Buy Now67.29%Canaccord Genuity
William Plovanic58%
$57 → $49MaintainsBuyGet Alert
05/02/2024Buy Now16.08%JP Morgan
Robbie Marcus67%
$42 → $34MaintainsOverweightGet Alert
05/02/2024Buy Now36.57%Needham
Mike Matson56%
$46 → $40MaintainsBuyGet Alert
04/23/2024Buy Now9.25%Oppenheimer
Suraj Kalia56%
→ $32UpgradePerform → OutperformGet Alert
04/10/2024Buy Now57.05%Needham
Mike Matson56%
$46 → $46ReiteratesBuy → BuyGet Alert
02/16/2024Buy Now98.02%UBS
Danielle Antalffy61%
$57 → $58MaintainsBuyGet Alert
02/16/2024Buy Now43.39%Stifel
Rick Wise73%
$50 → $42MaintainsBuyGet Alert
02/16/2024Buy Now57.05%Needham
Mike Matson56%
$44 → $46MaintainsBuyGet Alert
01/22/2024Buy Now94.61%UBS
Danielle Antalffy61%
$56 → $57MaintainsBuyGet Alert
01/04/2024Buy Now50.22%Needham
Mike Matson56%
$49 → $44MaintainsBuyGet Alert
11/29/2023Buy Now104.85%JMP Securities
Daniel Stauder48%
→ $60ReiteratesMarket Outperform → Market OutperformGet Alert
11/29/2023Buy Now67.29%Needham
Mike Matson56%
→ $49ReiteratesBuy → BuyGet Alert
11/02/2023Buy Now70.71%JP Morgan
Robbie Marcus67%
$60 → $50MaintainsOverweightGet Alert
11/02/2023Buy Now67.29%Needham
Mike Matson56%
$68 → $49MaintainsBuyGet Alert
10/23/2023Buy Now104.85%JMP Securities
Daniel Stauder48%
→ $60Initiates → Market OutperformGet Alert
09/29/2023Buy Now91.19%UBS
Danielle Antalffy61%
→ $56Initiates → BuyGet Alert
07/26/2023Buy Now132.16%Needham
Mike Matson56%
$60 → $68MaintainsBuyGet Alert
06/02/2023Buy Now104.85%Needham
Mike Matson56%
→ $60ReiteratesBuy → BuyGet Alert
05/03/2023Buy Now104.85%Needham
Mike Matson56%
$58 → $60MaintainsBuyGet Alert
04/17/2023Buy Now98.02%Needham
Mike Matson56%
→ $58MaintainsBuyGet Alert
02/22/2023Buy Now87.78%BTIG
Marie Thibault62%
$65 → $55MaintainsBuyGet Alert
02/22/2023Buy Now63.88%Stifel
Rick Wise73%
$55 → $48MaintainsBuyGet Alert
02/22/2023Buy Now152.65%Canaccord Genuity
William Plovanic58%
$81 → $74MaintainsBuyGet Alert
02/22/2023Buy Now98.02%Needham
Mike Matson56%
→ $58Reiterates → BuyGet Alert
02/06/2023Buy Now176.54%Canaccord Genuity
William Plovanic58%
$67 → $81MaintainsBuyGet Alert
12/19/2022Buy Now98.02%Needham
Mike Matson56%
$55 → $58MaintainsBuyGet Alert
11/02/2022Buy Now121.92%Canaccord Genuity
William Plovanic58%
$72 → $65MaintainsBuyGet Alert
11/02/2022Buy Now87.78%Needham
Mike Matson56%
$65 → $55MaintainsBuyGet Alert
10/17/2022Buy Now142.4%BTIG
Marie Thibault62%
$75 → $71MaintainsBuyGet Alert
08/03/2022Buy Now87.78%Piper Sandler
Matt O'Brien51%
$90 → $55MaintainsOverweightGet Alert
08/03/2022Buy Now121.92%Needham
Mike Matson56%
$55 → $65MaintainsBuyGet Alert
07/18/2022Buy Now70.71%Stifel
Rick Wise73%
$70 → $50MaintainsBuyGet Alert
06/28/2022Buy Now87.78%Needham
Mike Matson56%
$67 → $55MaintainsBuyGet Alert
06/24/2022Buy Now156.06%BTIG
Marie Thibault62%
$94 → $75MaintainsBuyGet Alert
05/04/2022Buy Now128.75%Needham
Mike Matson56%
$79 → $67MaintainsBuyGet Alert
05/04/2022Buy Now156.06%SVB Leerink
Danielle Antalffy61%
$95 → $75MaintainsOutperformGet Alert

FAQ

Q

What is the target price for AtriCure (ATRC) stock?

A

The latest price target for AtriCure (NASDAQ:ATRC) was reported by UBS on April 30, 2025. The analyst firm set a price target for $58.00 expecting ATRC to rise to within 12 months (a possible 98.02% upside). 31 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for AtriCure (ATRC)?

A

The latest analyst rating for AtriCure (NASDAQ:ATRC) was provided by UBS, and AtriCure maintained their buy rating.

Q

When was the last upgrade for AtriCure (ATRC)?

A

The last upgrade for AtriCure Inc happened on April 23, 2024 when Oppenheimer raised their price target to $32. Oppenheimer previously had a perform for AtriCure Inc.

Q

When was the last downgrade for AtriCure (ATRC)?

A

There is no last downgrade for AtriCure.

Q

When is the next analyst rating going to be posted or updated for AtriCure (ATRC)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AtriCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AtriCure was filed on April 30, 2025 so you should expect the next rating to be made available sometime around April 30, 2026.

Q

Is the Analyst Rating AtriCure (ATRC) correct?

A

While ratings are subjective and will change, the latest AtriCure (ATRC) rating was a maintained with a price target of $60.00 to $58.00. The current price AtriCure (ATRC) is trading at is $29.29, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch